Treatment of Diabetic Macular Edema: A Comparative Study.
10.3341/jkos.2010.51.6.849
- Author:
Yong Jun LEE
1
;
Kyung Seek CHOI
;
Sung Jin LEE
Author Information
1. Department of Ophthalmology, Soonchunhyang University College of Medicine, Seoul, Korea. ckseek@hosp.sch.ac.kr
- Publication Type:Comparative Study ; Original Article
- Keywords:
Diabetic macular edema;
Intravitreal injection;
Posterior subtenon injection;
Triamcinolone acetonide;
Bevacizumab
- MeSH:
Antibodies, Monoclonal, Humanized;
Humans;
Intraocular Pressure;
Intravitreal Injections;
Macular Edema;
Triamcinolone Acetonide;
Visual Acuity;
Bevacizumab
- From:Journal of the Korean Ophthalmological Society
2010;51(6):849-859
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: To compare the effect and complications of treatments for diabetic macular edema. METHODS: Literature review using the Korean medical database and the Korean Ophthalmological Society database was performed. Studies used consisted of patients with diabetic macular edema, comparing intravitreal triamcinolone acetonide (IVTA) injection with posterior subtenon triamcinolone acetonide (STTA) injection or intravitreal bevacizumab (IVB) injection, according to visual acuity (VA) outcomes, central macular thickness (CMT), and intraocular pressure (IOP) at 1, 3, and 6 months. RESULTS: In the three studies comparing IVTA injection with STTA injection, IVTA injection demonstrated greater improvement in VA at 1 month and CMT at 6 months. The patients who received IVTA injection had significantly higher IOP at 3 months. In the three studies comparing IVTA injection with IVB injection, IVTA injection demonstrated greater improvement in VA at 3 months and CMT at 6 months. CONCLUSIONS: The functional and anatomical improvements are achieved by IVTA injection, STTA injection, and IVB injection for diabetic macular edema, and the effect of IVTA injection is more prominent than other injection types with longer duration.
